Markers of tissue aging and uses therefor

Patent metadata

Field	Value
Publication number	US-11419864-B2
Application number	US-201816490287-A
Country	US
Kind code	B2
Filing date	Mar 2, 2018
Priority date	Mar 3, 2017
Publication date	Aug 23, 2022
Grant date	Aug 23, 2022

Abstract

Provided herein are methods of detecting or determining aging and/or oxidative damage in tissue, including placental tissue, skin, kidney and brain tissue. One embodiment provides a method for detecting or determining aging in body tissue, comprising measuring one or more markers of aldehyde oxidase 1 (AOX1) expression or activity in a biological sample, wherein the level of AOX1 expression or activity, or of the one or more markers, is indicative of aging in the tissue. Also provided herein are methods of treating a disease or condition associated with ageing or oxidative damage in one or more cells or tissues, comprising administering to a subject in need thereof an inhibitor of AOX1.

First claim

The invention claimed is:

1. A method of treating a disease or condition associated with ageing or oxidative damage in one or more cells or tissues, the method comprising:
selecting for treatment a subject in which the level of AOX1 expression or activity in a biological sample obtained from the subject, and comprising said cells or tissue, is increased relative to a reference value, wherein said increase in the level of expression or activity, of AOX1 is indicative of aging in said cells or tissue; and
administering to said subject in need thereof an inhibitor of aldehyde oxidase 1 (AOX1).

2. The method of claim 1 , wherein the subject is pregnant and the tissue is placental tissue.

3. The method of claim 1 , wherein the biological sample comprises blood, amniotic fluid, placental tissue or a sample derived therefrom.

4. The method of claim 2 , wherein the biological sample is of maternal origin.

5. The method of claim 2 , wherein the sample is maternal blood.

6. The method of claim 1 , wherein said increased AOX1 expression or activity is determined from free RNA or DNA, fragments of placental cells, exosomes, or microparticles present within the biological sample.

7. The method of claim 1 , wherein the level of AOX1 expression or activity is determined by the level of AOX1 mRNA and/or AOX1 protein.

8. The method of claim 7 , wherein the level of AOX1 expression or activity is further determined by measuring one or more markers of AOX1 activity, wherein said one or more markers are selected from 8-hydroxy-deoxyguanosine (8OHdG), 8-hydroxy-guanosinne (8HOG), 4-hydroxynonenal (4HNE) and malondialdehyde (MDA).

9. The method of claim 7 , wherein the level of AOX1 expression or activity is determined by the level of AOX1 mRNA and/or protein and 4HNE.

10. The method of claim 2 , wherein in the pregnant subject an increased level of expression or activity of AOX1, or of the one or more markers thereof, in the biological sample compared to a reference value is indicative of placental aging, pre-eclampsia, intra-uterine growth restriction, risk of post-dated pregnancy risk of stillbirth, a need for intervention to prevent post-dated pregnancy or stillbirth or an appropriate time to deliver a baby.

11. The method of claim 10 , wherein the intervention to prevent post-dated pregnancy or stillbirth comprises prophylactic caesarean section, induction of labor and/or administration of a therapy to prevent or delay placenta ageing or prolong viability of the fetus in utero.

12. The method of claim 2 , wherein the disease or condition associated with placental aging comprises pre-eclampsia, intra-uterine growth restriction, or stillbirth.

Assignees

• Univ Newcastle

Inventors

• Smith Roger
• Maiti Kaushik

Classifications

• A61P15/06

  Antiabortive agents; Labour repressants · CPC title

• A61P15/00

  Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives · CPC title

• A61K31/473 Primary

  ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines · CPC title

• A61K31/4535

  containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen · CPC title

• A61K45/00 Primary

  Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00 · CPC title